Skip to main content
SpringerLink
Log in

Endometrium

  • Chapter
Cancer Precursors

  • 223 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000; 76:287–90.

    Article  PubMed  CAS  Google Scholar 

  2. Mutter GL, Baak JP, Crum CP, et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190:462–9.

    Article  PubMed  CAS  Google Scholar 

  3. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13:295–308.

    Article  PubMed  CAS  Google Scholar 

  4. Scully RE, Bonfiglio TA, Kurman RJ, et al. Histological typing of female genital tract tumours. World Health Organization International Histological Classification of Tumours, 2nd ed. Berlin: Springer-Verlag, 1994, pp. 13–28.

    Google Scholar 

  5. Ferenczy A, Mutter G. Endometrial hyperplasia and neoplasia: Definition, diagnosis and management Principles. In: Sciarra J (ed) Gynecology and obstetrics looseleaf CD-ROM, Lippincott, Williams & Wilkins, 2000. Philadelphia.

    Google Scholar 

  6. Mutter GL. Premalignant Lesions of the Endometrium. A project from the Endometrial Collaborative Group. Available at URL: http://www.endometrium.org/.

  7. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92:924–30.

    Article  PubMed  CAS  Google Scholar 

  8. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998; 22:1012–19.

    Article  PubMed  CAS  Google Scholar 

  9. Bergeron C, Nogales FF, Masseroli M, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999; 23:1102–8.

    Article  PubMed  CAS  Google Scholar 

  10. Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol 2000; 13:309–27.

    Article  PubMed  CAS  Google Scholar 

  11. Pettersson B, Adami HO, Lindgren A, et al. Endometrial polyps and hyperplasia as risk factors for endometrial carcinoma. A case-control study of curettage specimens. Acta Obstet Gynecol Scand 1985; 64:653–9.

    PubMed  CAS  Google Scholar 

  12. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6:93–108.

    PubMed  CAS  Google Scholar 

  13. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16:600–10.

    PubMed  CAS  Google Scholar 

  14. Moll UM, Chalas E, Auguste M, et al. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol 1996; 27:1295–300.

    Article  PubMed  CAS  Google Scholar 

  15. Deligdisch L, Holinka CF. Endometrial carcinoma: two diseases? Cancer Detect Prev 1987; 10:237–46.

    PubMed  CAS  Google Scholar 

  16. Hoffman K, Nekhlyudov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol 1995; 58:198–201.

    Article  PubMed  CAS  Google Scholar 

  17. Sherman ME, Silverberg SG. Advances in endometrial pathology. Clin Lab Med 1995; 15:517–43.

    PubMed  CAS  Google Scholar 

  18. Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997; 10:963–8.

    PubMed  CAS  Google Scholar 

  19. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26:1260–7.

    Article  PubMed  CAS  Google Scholar 

  20. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26:1268–74.

    Article  PubMed  CAS  Google Scholar 

  21. Sherman ME, Sturgeon S, Brinton L, et al. Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. J Cell Biochem Suppl 1995; 23:160–4.

    PubMed  CAS  Google Scholar 

  22. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827–41.

    PubMed  CAS  Google Scholar 

  23. Ries LAG, Eisner MP, Kosary CL, et al. (eds) SEER Cancer Statistics Review, 1973–1997. Bethesda, MD: National Cancer Institute, 2000.

    Google Scholar 

  24. National Cancer Institute of Canada. Canadian Cancer Statistics 2000. Toronto, Canada: National Cancer Institute of Canada, 2000.

    Google Scholar 

  25. Dhom G. Epidemiology of hormone-depending tumors. In:Voigt KD, Knabbe C (eds) Endocrine dependent tumors. New York: Raven Press, 1991, pp. 26–35.

    Google Scholar 

  26. Hill HA, Eley JW, Harlan LC, et al. Racial differences in endometrial cancer survival: the black/white cancer survival study. Obstet Gynecol 1996; 88:919–26.

    Article  PubMed  CAS  Google Scholar 

  27. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995; 75(1 Suppl):270–94.

    PubMed  CAS  Google Scholar 

  28. SEER Cancer Incidence Public-Use Database, 1973–1995. August, 1997, submission. US Department of Health and Human Services, April, 1998.

    Google Scholar 

  29. Franco EL. Epidemiology of uterine cancers. In: Meisels A, Morin C (eds) Cytopathology of the uterus, 2nd Ed. Chicago: American Society of Clinical Pathologists, 1997 (pp. 301–24).

    Google Scholar 

  30. Schottenfeld D. Epidemiology of endometrial neoplasia. J Cell Biochem 1995; 23(Suppl.):151–9.

    CAS  Google Scholar 

  31. Barrett RJ 2nd, Harlan LC, Wesley MN, et al. Endometrial cancer: stage at diagnosis and associated factors in black and white patients. Am J Obstet Gynecol 1995; 173:414–22; discussion 422-3.

    Article  PubMed  Google Scholar 

  32. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985; 56:403–12

    PubMed  CAS  Google Scholar 

  33. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989; 160:126–31.

    PubMed  CAS  Google Scholar 

  34. Feldman S, Cook EF, Harlow BL, et al. Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 1995; 56:376–81.

    Article  PubMed  CAS  Google Scholar 

  35. Ben-Yehuda OM, Kim YB, Leuchter RS. Does hysteroscopy improve upon the sensitivity of dilatation and curettage in the diagnosis of endometrial hyperplasia or carcinoma? Gynecol Oncol 1998; 68:4–7.

    Article  PubMed  CAS  Google Scholar 

  36. Farquhar CM, Lethaby A, Sowter M, et al. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 1999; 181:525–9.

    Article  PubMed  CAS  Google Scholar 

  37. Gredmark T, Kvint S, Havel G, et al. Adipose tissue distribution in postmenopausal women with adenomatous hyperplasia of the endometrium. Gynecol Oncol 1999; 72:138–42.

    Article  PubMed  CAS  Google Scholar 

  38. Anastasiadis PG, Skaphida PG, Koutlaki NG, et al. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol 2000; 21:131–4.

    PubMed  CAS  Google Scholar 

  39. Koss LG, Schreiber K, Oberlander SG, et al. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 1984; 64:1–11.

    PubMed  CAS  Google Scholar 

  40. Koss LG. Detection of occult endometrial carcinoma. J Cell Biochem Suppl 1995; 23:165–73.

    PubMed  CAS  Google Scholar 

  41. Vuento MH, Pirhonen JP, Makinen JI, et al. Screening for endometrial cancer in asymptomatic postmenopausal women with conventional and colour Doppler sonography. Br J Obstet Gynaecol 1999; 106:14–20.

    PubMed  CAS  Google Scholar 

  42. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994; 170:1213–23.

    PubMed  CAS  Google Scholar 

  43. Archer DF, Furst K, Tipping D, et al. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999; 94:498–503.

    PubMed  CAS  Google Scholar 

  44. Kurman RJ, Felix JC, Archer DF, et al. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000; 96:373–9.

    Article  PubMed  CAS  Google Scholar 

  45. Bjarnason K, Cerin A, Lindgren R, et al. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999; 32:161–70.

    Article  PubMed  CAS  Google Scholar 

  46. Bergeron C, Fox H. Low incidence of endometrial hyperplasia with acceptable bleeding patterns in women taking sequential hormone replacement therapy with dydrogesterone. Gynecol Endocrinol 2000; 14:275–81.

    PubMed  CAS  Google Scholar 

  47. Baak JP, Wisse-Brekelmans EC, Fleege JC, et al. Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Pathol Res Pract 1992; 188:856–9.

    PubMed  CAS  Google Scholar 

  48. Hunter JE, Tritz DE, Howell MG, et al. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia. Gynecol Oncol 1994; 55:66–71.

    Article  PubMed  CAS  Google Scholar 

  49. Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecol Oncol 1994; 52:373–8.

    Article  PubMed  CAS  Google Scholar 

  50. Ho SP, Tan KT, Pang MW, et al. Endometrial hyperplasia and the risk of endometrial carcinoma. Singapore Med J 1997; 38:11–15.

    PubMed  CAS  Google Scholar 

  51. Lindahl B, Willen R. Endometrial hyperplasia following estrogen treatment without the addition of gestagen. A follow-up study after withdrawal of estrogens. Anticancer Res 1991; 11:2071–3.

    PubMed  CAS  Google Scholar 

  52. Parazzini F, La Vecchia C, Bocciolone L, et al. The epidemiology of endometrial cancer. Gynecol Oncol 1991; 41:1–16.

    Article  PubMed  CAS  Google Scholar 

  53. Weber AM, Belinson JL, Piedmonte MR. Risk factors for endometrial hyperplasia and cancer among women with abnormal bleeding. Obstet Gynecol 1999; 93:594–8.

    Article  PubMed  CAS  Google Scholar 

  54. Daly MB, Bookman MA, Lerman CE. Female reproductive tract: cervix, endometrium, ovary. In: Greenwald P, Kramer BS, Weed DL (eds) Cancer Prev Control. New York: Marcel Dekker, 1995, pp. 585–610.

    Google Scholar 

  55. Brinton LA, Barrett RJ, Berman ML, et al. Cigarette smoking and the risk of endometrial cancer. Am J Epidemiol 1993; 137:281–91.

    PubMed  CAS  Google Scholar 

  56. Weir HK, Sloan M, Kreiger N. The relationship between cigarette smoking and the risk of endometrial neoplasms. Int J Epidemiol 1994; 23:261–6.

    PubMed  CAS  Google Scholar 

  57. Sturgeon SR, Sherman ME, Kurman RJ, et al. Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev 1998; 7:231–5.

    PubMed  CAS  Google Scholar 

  58. Grady D, Ernster VL. Endometrial cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention. New York: Oxford University Press, 1996, pp. 1058–89.

    Google Scholar 

  59. Kreiger N, Marrett LD, Clarke EA, et al. Risk factors for adenomatous endometrial hyperplasia: a case-control study. Am J Epidemiol 1986; 123:291–301.

    PubMed  CAS  Google Scholar 

  60. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999; 353:1824–8.

    Article  PubMed  CAS  Google Scholar 

  61. Horwitz RI, Feinstein AR. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978; 299:1089–94.

    PubMed  CAS  Google Scholar 

  62. Rothman KJ, Greenland S. Modern Epidemiology, 2nd ed. Philadelphia: Lipincott-Raven, 1998, pp. 139–40.

    Google Scholar 

  63. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275:370–5.

    Google Scholar 

  64. Grimbizis G, Tsalikis T, Tzioufa V, et al. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Hum Reprod 1999; 14:479–84.

    Article  PubMed  CAS  Google Scholar 

  65. Beral V. Exogenous sex hormones and cancer. In: Lilienfeld AM (ed) Reviews in cancer epidemiology. New York: Elsevier, 1980, pp. 126–30.

    Google Scholar 

  66. Kendrick JS, Wingo P, Rubin GL, et al. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987; 257:796–800.

    Google Scholar 

  67. Burke TW, Tortolero-Luna G, Malpica A, et al. Endometrial hyperplasia and endometrial cancer. Obstet Gynecol Clin North Am 1996; 23:411–56.

    PubMed  CAS  Google Scholar 

  68. Fisher B, Costantino JP, Redmond CK. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527–37.

    PubMed  CAS  Google Scholar 

  69. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer. Cancer Res 1988; 48:246–53.

    PubMed  CAS  Google Scholar 

  70. Baanders-van Halewyn EA, Blankenstein MA, Thijssen JH, et al. A comparative study of risk factors for hyperplasia and cancer of the endometrium. Eur J Cancer Prev 1996; 5:105–12.

    PubMed  CAS  Google Scholar 

  71. La Vecchia C, Decarli A, Fasoli M, et al. Nutrition and diet in the etiology of endometrial cancer. Cancer 1986; 57:1248–53.

    PubMed  Google Scholar 

  72. Bakour SH, Khan KS, Gupta JK. The risk of premalignant and malignant pathology in endometrial polyps. Acta Obstet Gynecol Scand 2000; 79:317–20.

    Article  PubMed  CAS  Google Scholar 

  73. Cherkis RC, Patten SF Jr, Dickinson JC, et al. Significance of atypical endometrial cells detected by cervical cytology. Obstet Gynecol 1987; 69:786–9.

    PubMed  CAS  Google Scholar 

  74. Kurman RJ, Solomon D. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses: Definitions, criteria, and explanatory notes for terminology and specimen adequacy. New York: Springer, 1994.

    Google Scholar 

  75. Gomez-Fernandez CR, Ganjei-Azar P, Behshid K, et al. Normal endometrial cells in Papanicolaou smears: prevalence in women with and without endometrial disease. Obstet Gynecol 2000; 96:874–8.

    Article  PubMed  CAS  Google Scholar 

  76. Nguyen TN, Bourdeau JL, Ferenczy A, et al. Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia. Diagn Cytopathol 1998; 19:89–93.

    Article  PubMed  CAS  Google Scholar 

  77. Hakala T, Mecklin JP, Forss M, et al. Endometrial carcinoma in the cancer family syndrome. Cancer 1991; 68:1656–9.

    PubMed  CAS  Google Scholar 

  78. Yancey M, Magelssen D, Demaurez A, et al. Classification of endometrial cells on cervical cytology. Obstet Gynecol 1990; 76:1000–5.

    PubMed  CAS  Google Scholar 

  79. Ferenczy A. Methods for detecting endometrial carcinoma and its precursors. In: Buchsbaum HJ, Sciarra JJ (eds) Gynecology and obstetrics, Vol. 4. New York: Harper & Row, 1982, pp. 1–8.

    Google Scholar 

  80. Tsuda H, Kawabata M, Yamamoto K, et al. Prospective study to compare endometrial cytology and transvaginal ultrasonography for identification of endometrial malignancies. Gynecol Oncol 1997; 65:383–6.

    Article  PubMed  CAS  Google Scholar 

  81. Grimes DA. Diagnostic dilation and curettage: a reappraisal. Am J Obstet Gynecol 1982; 142:1–6.

    PubMed  CAS  Google Scholar 

  82. Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding—a Nordic multicenter study. Am J Obstet Gynecol 1995; 172:1488–94.

    Article  PubMed  CAS  Google Scholar 

  83. Goldstein SR. Saline infusion sonohysterography. Clin Obstet Gynecol 1996; 39:248–58.

    Article  PubMed  CAS  Google Scholar 

  84. Takahashi S, Murakami T, Narumi Y, et al. Preoperative staging of endometrial carcinoma: diagnostic effect of T2-weighted fast spin-echo MR imaging. Radiology 1998; 206:539–47.

    PubMed  CAS  Google Scholar 

  85. Pritchard KI. Screening for endometrial cancer: is it effective? Ann Intern Med 1989; 110:177–9.

    PubMed  CAS  Google Scholar 

  86. Screening for Endometrial Cancer (PDQ). Screening/Detection—Health Professionals. US National Cancer Institute. Updated: August, 2000. Available at URL: http://cancernet.nci.nih.gov/pdq/pdq_screening.shtml.

  87. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994; 30A:1714–21.

    PubMed  CAS  Google Scholar 

  88. Suh-Burgmann EJ, Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med 1999; 131:127–35.

    PubMed  CAS  Google Scholar 

  89. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170:447–51.

    PubMed  CAS  Google Scholar 

  90. Barakat RR. Benign and hyperplastic endometrial changes associated with tamoxifen use. Oncology 1997; 11(2 Suppl 1):35–7.

    PubMed  CAS  Google Scholar 

  91. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 2000; 7:73–83.

    Article  PubMed  CAS  Google Scholar 

  92. Agorastos T, Bontis J, Vakiani A, et al. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol 1997; 65:102–14.

    Article  PubMed  CAS  Google Scholar 

  93. Spitz IM, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women’s health. Steroids 2000; 65:807–15.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Eduardo L. Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex Ferenczy
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Oncology and Epidemiology, McGill University, Montreal, Quebec, H2W 1S6, Canada

    Eduardo L. Franco MPH, DrPH (Professor, Director) (Professor, Director)

  2. Division of Cancer Epidemiology, McGill University, Montreal, Quebec, H2W 1S6, Canada

    Eduardo L. Franco MPH, DrPH (Professor, Director) (Professor, Director)

  3. Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, 10461, USA

    Thomas E. Rohan MB, BS, PhD (Professor and Chairman) (Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Franco, E.L., Ferenczy, A. (2002). Endometrium. In: Franco, E.L., Rohan, T.E. (eds) Cancer Precursors. Springer, New York, NY. https://doi.org/10.1007/0-387-21605-7_18

Download citation

  • DOI: https://doi.org/10.1007/0-387-21605-7_18

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95188-1

  • Online ISBN: 978-0-387-21605-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation